E6AP was originally identified as the ubiquitin-protein ligase involved in human papillomavirus (HPV) E6-mediated p53 degradation and has since been shown to act as an E3 ubiquitin-protein ligase in the ubiquitination of several other protein substrates. To further define E6AP function at the molecular and cellular levels, a ribozyme-based gene inactivation approach was adopted. A library of hammerhead ribozymes, with randomized arm sequences, was used to screen active molecules along the entire E6AP transcript for ribozyme-cleavable sites. Ligation-anchored PCR was adapted to detect cleavage products, and ribozymes designed to the selected sites were characterized both in vitro and in vivo. Ribozyme-mediated reduction in E6AP expression was found to enhance the apoptotic response of HeLa cells to mitomycin C-induced DNA damage. These findings suggest that E6AP has potential as a drug target, as its suppression can potentiate apoptosis in HPV-positive cells treated with a cytotoxic drug.
T he ubiquitin-dependent proteolytic pathway has emerged as a crucial mechanism in cellular regulation. 1 Protein ubiquitination involves a cascade of cellular enzymes called E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme) and E3 (ubiquitin-protein ligase). Ubiquitin is activated at its C-terminal glycine to form a thiolester with the active site cysteine on E1 in an ATP-dependent reaction. The activated ubiquitin is then transferred to one of a family of E2s, preserving the high-energy thiolester bond. E2 enzymes catalyze isopeptide bond formation between ubiquitin and substrate protein directly or in association with an E3. Multiubiquitinated proteins are recognized by a large multisubunit protease complex, the 26S proteosome and degraded.
The 100 kDa cellular protein E6AP, in association with human papillomavirus (HPV) E6, was initially identified as a ubiquitin-protein ligase responsible for p53 degradation. 2 It has since been shown that E6AP acts as an E3 in the ubiquitin-dependent proteolysis of various other cellular proteins, both in the presence and absence of HPV E6. [3] [4] [5] [6] [7] E6AP was also the founding member of a family of structurally related E3s carrying a carboxyl terminus that is highly conserved among various organisms, termed the hect domain (homology to E6AP C terminus). 8 Besides its protein ligase function, E6AP
was recently shown to act as a coactivator in nuclear hormone receptor-mediated transactivation, 9 and mutations in E6AP have been causally linked with a genetic neurological disorder known as Angelman Syndrome. 10, 11 Despite the identification of several E6AP-interacting proteins, the role of E6AP in cellular physiology remains poorly understood. Recent works from several groups suggest that E6AP may be involved in the regulation of important cellular processes such as transcription, signal transduction, cell survival and/or apoptosis, cell-cycle control and DNA repair. [3] [4] [5] [6] [7] 9 Hammerhead ribozymes are catalytic RNA molecules that possess conserved catalytic core sequences flanked by two hybridizing arms (stems I and III). 12 Substrate cleavage occurs 3 0 to the nucleotide sequence NUH, where N is any nucleotide and H can be any nucleotide except G. The high degree of specificity and efficiency in substrate binding and cleavage makes ribozymes a valuable tool for gene function analysis. Although the technology seems relatively straightforward, ribozymeaccessibility within a highly structured target RNA remains a significant impediment to designing effective ribozymes. Toward this end, an empirical approach represents a more accurate means of identifying the most effective cleavage site(s) for ribozymes. Among several different approaches, [13] [14] [15] [16] [17] Lieber and Strauss 18 used a ribozyme library carrying a conserved catalytic domain and randomized hybridizing arm sequences, and 5 0 RACE to detect the most accessible sites in the human growth hormone transcript. Despite the elegant principle that underlies this method, its high technical demand appears to have deterred others from utilizing it.
In the present study, a modified strategy is employed in the selection of efficient E6AP ribozymes to further define E6AP gene function. Using a synthetic combinatorial library of ribozymes and ligation-anchored PCR (LA-PCR), 19 several ribozyme-cleavable sites within the E6AP transcript were identified. Characterization of ribozymes designed to the selected sites enabled the identification of active agents to gain further insight into the role of E6AP within cells. This was achieved by expression of the anti-E6AP ribozyme in HeLa cells where the effect of the downregulation of the E6AP on cell-cycle regulation and apoptosis was examined. The findings from this study support E6AP's involvement in HPV-mediated suppression of p53 and resistance to cytotoxic drug-induced apoptosis. It also demonstrated the potential of E6AP as a drug target for overcoming HPV-positive tumor-related resistance to cytotoxic therapy-induced cell death.
Methods

Oligonucleotides
All oligonucleotides were purchased from Pacific Oligos unless specified otherwise.
Construction of random ribozyme library
A single-stranded oligonucleotide RRz-ss (GTGCCAA-GCTTACCGCGG(N) 12 CTGATGAGTCCGTGAGGA-CGAAAX(N) 11 
CCTAGGTCGCCATCTCTTCC3
0 , where N is 25% each of A, C, G and T, and X is 40% C, 40% G, 10% T, 10% A) (Macromolecular Resources) was used to generate the double-stranded random ribozyme gene by PCR (Fig 1) . The reaction was carried out using 50 ng RRz-ss, in 1 Â PCR buffer II (Perkin-Elmer) with 2.5 mM MgCl 2 , 2.5 mM each of dGTP, dATP, dCTP, dTTP, 50 pmol of each forward primer (T7-XD10: 5 0 TAATAC-GACTCACTATAGGGAGAGTGCCAAGCTTACC-G3 0 ) and reverse primer (XD-11: 5 0 GGAAGAGATGGC-GAC3 0 ). Amplification was carried out using 1 U of AmpliTaq DNA polymerase (Perkin-Elmer), through 25 thermocycles at 921C for 10 s, 501C for 30 s and 721C for 30 s. The T7 phage promoter sequence was introduced to the coding strand of the amplicons to enable direct transcription of the ribozyme library. In all, 17 amplification reactions were performed in total and pooled in order to get full representation of ribozyme species. A 1 mg aliquot was used for in vitro transcription at 371C for 1 hour using an RNA transcription kit (Stratagene). The synthetic ribozyme library was designated T7-RRz.
Preparation of E6AP substrate RNA E6AP transcription vector pcE6AP was constructed by subcloning the E6AP cDNA from pGEM150-120 (gift of Dr JM Huibregtse) into pcDNA3.1(À) (Invitrogen). The plasmid was linearized using HindIII and purified by electrophoresis in a 1% agarose gel. The linearized template was extracted from the agarose with Gene Clean (Bio 101). For the production of unlabeled RNA, in vitro transcription of full-length E6AP RNA was performed with 1 mg of purified template DNA using an RNA transcription kit (Epicentre Technologies) for 2 hours at 371C. Full-length transcript was purified by electrophoresis in a 3.5% denaturing polyacrylamide gel before being eluted into 0.3 M sodium acetate at 371C overnight and ethanol precipitated. A 32 P-labeled transcript was synthesized for kinetic analysis on the same template DNA by in vitro transcription in the presence of 2 mCi/ml [a-32 P]UTP (GeneWorks). The reagents and T7 RNA polymerase for this reaction were supplied in an RNA transcription kit (Stratagene).
Detection of cleavage products by ligation-anchored PCR (LA-PCR)
In vitro cleavage was carried out using 2 mg of the transcribed E6AP RNA and 5 mg of random ribozymes, in a final volume of 20 ml. Reactions were performed in 50 mM Tris-HCl, pH 7.5, 10 mM MgCl 2 at 371C for 1 hour without prior heat denaturation. Primer-extension analysis was performed on ribozyme-cleaved RNA using Superscript II reverse transcriptase (Life Technologies). Seven E6AP-specific primers (474R:CCGGAAGCTCT-G TACCAATGCCTCA; 783R: CAAGTCACATTCCA-CGTTAGGTGAC; 1185R: GCTGGACTCAGGGATG-GGCTCTTCA; 1593R: CTCTAGCCGGACAAGTG-CATCATCT; 1950R: CTGATATAGAACTGGGTGA-GAGTCT; 2276R: GCTTGGAAATCTAGATTGCG- Amplification by PCRgenerated double-stranded random ribozyme templates that were used for direct transcription from the attached T7 promoter.
E6AP gene suppression using ribozymes Y Kim et al GCTTC; GSP1: TTACAGCATGCCAAATCCTTTGG-CA) were designed at 300-400 base intervals in order to minimize the production of partial cDNAs. In each reaction, 2 pmol primer was combined with one-tenth of cleavage reaction products and reactions were performed as described. 20 Following cDNA first-strand synthesis, the RNA was removed with 1 U RNase H (Roche Biochemicals) at 371C for 30 minutes. The single stranded (ss) DNA was extracted with phenol-chloroform-isoamylalcohol (25:24:1) and precipitated with ethanol. The ssDNA was resuspended in minimal volume and added to a ligation mixture containing 1.5 pmol of linker oligo DT88 (5 0 -PO 4 -GAAGAGAAGGTGGAAATGGCGTT-TTGG-cordycepin-3 0 ), 50 mM Tris-HCl (pH 8.0), 10 mM MgCl 2 , 20 mM ATP, 25% PEG8000, 10 mg/ml bovine serum albumin, and 10 U T4 RNA ligase (New England Biolabs). The ligation reaction was carried out in a final volume of 10 ml for approximately 16 hours at 221C. The ligation products were ethanol precipitated and resuspended in 10 ml before being used as template for the PCR phase of the procedure.
Amplification was carried out using 2.5 U AmpliTaq DNA polymerase (Perkin-Elmer) in 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2.5 mM MgCl 2 , 200 pM dNTP and 10 pmol of each forward and reverse primer, in a 50 ml reaction volume. The forward primer used in these reactions was DT89 (5 0 CCAAAACGCCATTTCCACC-TTCTCTTC3 0 ), which consisted of sequence complementary to the ligated linker DT88. Each of the 32 P-labelled reverse primers (N474R: GCCTCAGCACTA-GAAAAAACTCTTC; N783R: GGTGACAAATATA-CAAGTGCATTGA; N1185R: CTTCATCATCTTCT-TCATTGTGATT; N1583R: CATCTATGATATGGT-CACGTCTAAC; N1950R: GAGTCTCCCAAGTCAC-GAAAAGTTC; N2276R: GCGGCTTCCACATATAA-GCAATTCA; NGSP1: GGCATACGTCATGGCCTT-CAACAAT) were nested with respect to the primers used to synthesize the first strand. PCR was performed over 25 cycles (45 s at 941C, 60 s at 651C, 90 s at 721C or 45 s at 941C, 60 s at 601C, 90 s at 721C). The reaction mixture was combined with stop buffer (formamide, EDTA, loading dye) before electrophoresis on a 6% denaturing polyacrylamide gel.
Cleavage experiments using random ribozymes were carried out at least four times. The relative intensity of the cleavage products was estimated and ranked, taking into consideration the frequency of the particular products detected. Sequencing fragments corresponding to each segment of the target were also generated by primer extension on the double-stranded DNA template in the presence of chain-terminating dideoxynucleotides (ddNTP) as described by Cairns et al. 20 Cleavage products were identified by alignment with the respective sequence ladders, and then counted back 27 bases to compensate for linker sequence. Ribozymes targeted to these sites were designed with 12 nt-12 nt hybridizing arms. The ribozyme templates were synthesized as single-stranded oligonucleotides for sense and antisense strands and then annealed. Oligonucleotides for ribozyme templates were designed with BstBI restriction sites. A measure of 1 mg of each pair of oligonucleotides was combined in H 2 O to a total volume of 20 ml and denatured at 951C for 2 minutes, before being allowed to gradually cool down to room temperature. The annealed inserts were cloned into the 3 0 end of the neomycin gene (neo) in pIND (Invitrogen). Plasmids were purified by cesium chloride centrifugation.
Cloning of ribozymes and template preparation
In order to prepare ribozymes for use in in vitro cleavage analysis, the ribozyme-expressing pIND clones were used to generate ribozyme templates by PCR. A T7 promoter was incorporated into the forward primer pIND-Rz5 0 : 5 0 TAATACGACTCACTATAGGGAGAC-GGGACTCTGGGGTT3 0 , which was specific for the neo region immediately before the ribozyme. The reverse primer pIND-Rz3 0 : 5 0 CTTGGTCGGTCATTT3 0 was complementary to the sequence immediately 3 0 of the ribozyme. Double-stranded ribozyme template was generated by PCR in 1 Â PCR buffer II (Perkin-Elmer), 2.5 mM MgCl 2 , 200 mM dNTPs, and 1 mM of each forward and reverse primers. The amplification was carried out using 2 U of AmpliTaq DNA polymerase (Perkin-Elmer) through 25 thermocycles: 941C for 30 s, 501C for 1 minutes, 721C for 1.5 minutes. In all, 1 mg of PCR generated template was used to transcribe the ribozymes. In vitro transcription was performed according to the conditions described previously, using an RNA transcription kit (Stratagene).
Cleavage kinetics
In vitro cleavage kinetics of the selected ribozymes were determined under single-turnover conditions as described by Heidenreich and Eckstein 21 and Heidenreich et al. 22 Full-length 32 P-labeled E6AP transcript (10 nM) was mixed with 50, 200, 400, 750 and 1000 nM of individual ribozyme. The reaction was initiated by the addition of cleavage buffer to final concentrations of 50 mM TrisHCl, pH 7.5 and 10 mM MgCl 2 in a reaction volume of 10 ml. Reactions were allowed to proceed at 371C for 1 hour and were then quenched in an equal volume of stop solution (formamide, EDTA, loading dye). Products were analyzed on denaturing polyacrylamide gels. The extent of reaction at each ribozyme concentration was determined by densitometry of the phosphorimage using ImageQuant software (Molecular Dynamics). Kinetic constants for the cleavage of E6AP RNA were obtained by plotting the observed cleavage rate k obs against the quotient of k obs over the ribozyme concentration [E], as described by Heidenreich et al. 22 
Cell transfection
HeLa cells (ATCC CCL2) were grown in Dulbecco's modified Eagle's medium (Gibco-BRL), supplemented with 10% heat-inactivated fetal bovine serum, l-glutamine and penicillin/streptomycin. The cells were E6AP gene suppression using ribozymes Y Kim et al transfected with pINDRz354, pINDRz420, pINDRz687 and pINDRz1584, using DOTAP liposomal transfection reagent according to the manufacturer's instructions (Roche, Biochemicals). Stable cell lines were established by G418 selection (500 mg/ml) and designated HeLaRz2, HeLaRz3, HeLaRz4 and HeLaRz5, respectively. In addition, a rationally designed ribozyme targeted to a GUC site at position 142 (Rz1) was also cloned into the vector. A clonal version of HeLaRz5 designated HeLaRz5c was also prepared from single-cell dilutions.
Western blot analysis
Total cellular protein was extracted using RIPA buffer with protease inhibitors, 1 mg/ml aprotinin and 100 mg/ml PMSF. A total of 50-100 mg of cell lysates was separated on 10% SDS polyacrylamide and electroblotted onto PVDF (Millipore). Membranes were probed at room temperature with polyclonal anti-E6AP (gift of Dr PR Daniels), c-Myc (Upstate) or monoclonal anti-Bak (BDParmingen), P53(Santa Cruz), b-actin antibody (Sigma). Specific protein bands were visualized by enhanced chemiluminescence reagent (Amersham) and quantified using the Personal Densitometer (Amersham).
Cell-cycle analysis
Exponentially growing cells were treated with 10 mg/ml mitomycin C (MMC) (Sigma) for 18 hours and stained for DNA content as described by Butz et al. 23 The cell cycle was analyzed on FACSort (Becton Dickinson) in the CellQuest program. Quantitation of apoptotic cells was performed by measuring the area under the sub-G1 region as a percentage of the total number of cells.
Gene expression profiling
The gene expression profile of E6AP ribozyme expressing Hela cells was compared to that of HeLa cells containing the vector alone using the Clonetech Atlas macroarray system. In each case, total RNA was extracted from the cells using the Atlas Pure Total RNA Labeling System (Clontech) according to the manufacturer's instructions. RNA was also extracted further with saturated phenol and chloroform, and then ethanol precipitated. Messenger RNA was then purified from total RNA using the Oligotex mRNA Isolation Kit (Qiagen).
Radiolabeled cDNA probes were prepared from the mRNA template by reverse transcription. Briefly, the Atlas DNA-specific primer mix was annealed to 1 mg of mRNA at 701C for 2 minutes prior to incubation at 501C for 25 minutes in a reaction mix (50 mM Tris-HCl pH 8. Prehybridization of each array was performed at 681C for 30 minutes with ExpressHyb (Clontech) containing heat-denatured sheared salmon testes DNA (Stratagene).
After denaturation in 100 mM NaOH, the labeled cDNA probe was neutralized (500 mM NaH 2 PO 4 , pH 7.0) and added to a final concentration of 1 Â 106 cpm/ml in ExpressHyb. Hybridization was performed overnight with continuous agitation at 681C. The arrays were washed four times with solution 1 (2 Â SSC, 1% SDS) at 681C for 30 minutes per wash and then twice with solution 2 (0.1 Â SSC, 0.5% SDS) at 681C for 30 minutes each.
Radioimage detection and quantification was performed using a Phosphorimager after exposing arrays to phosphor-storage screens for up to 6 days. The coordinates of genes that were under-or overexpressed were identified and their intensity measured and normalized to the b-actin signals using ImageQuant software.
Genes found to be significantly under-or overexpressed by arrays were confirmed by conventional Northern blot analysis. Total RNA was extracted and fractionated on a 1.4% denaturing agarose gel. After capillary transfer and UV crosslinking to a nylon membrane, the RNA and its support were subjected to prehybridization with ExpressHyb solution. Hybridization with 32 P-end-labeled 35-mer oligonucleotide probes was carried out in ExpressHyb at 681C for 1 hour. After multiple washes in various concentrations of SSC, membranes were exposed to screens for phosphorimaging. Expression levels were normalized with respect to b-actin.
Results
Ribozyme library construction
A ribozyme gene library was generated by PCR from a single-stranded template, with conserved sequences in the catalytic domain and randomized sequences in the hybridizing arms (Fig 1) . With a total of 24 nt in the randomized hybridizing arms, it was possible to generate a library containing in the order of 10 14 ribozyme variants. To produce this complete library from a fully randomized template pool, 20 mg of template DNA would be required. In this selection, we used a partial library consisting of at most 10 11 variants.
RNA cleavage detection by LA-PCR
In order to detect and identify rare cleavage events in the E6AP RNA transcript caused by a relatively small number of specific members of the ribozyme library, we harnessed the power of PCR. As the cDNA generated is only defined at one end, we used a PCR methodology with single-sided specificity known as LA-PCR (Fig 2) . To establish conditions amenable to cleavage product detection, each step of the procedure was carefully examined using RNA fragments generated by a single ribozyme. The most critical element of this technique, the single-stranded ligation reaction, was optimized in various concentrations of polyethyleneglycol (PEG) and hexamine cobalt chloride (HCC), with a range of linker to cDNA ratios. 24 It was found that a donor:acceptor ratio of 5:1 in buffer containing 25% PEG and no HCC was optimal for the linker ligation. The identity of cleavage product amplicons was determined by alignment E6AP gene suppression using ribozymes Y Kim et al with a sequencing ladder and their relationship to a ribozyme validated by the analysis of an LA-PCRamplified cleavage product generated by a ribozyme with a known target site. When the E6AP transcript was challenged with the library, we consistently saw the same pattern of intense banding compared to the uncleaved control, which potentially represented the cleavage products of efficient ribozymes (Fig 3) . To identify the selected ribozymes responsible for these amplicons, their positions were aligned with sequencing fragments. The positions of the cleavage sites and their relative intensities are summarized in Table 1 . While these amplicons were scattered throughout the target transcript, there was a peak in activity in the region between positions 354 and 687. These sites may have corresponded with a more accessible area in terms of secondary structure. A survey of the triplets selected for cleavage revealed that only one contained a GUC triplet. This was surprising given the initial bias in the library (Fig 1a) and the fact that GUC is considered to be the most efficient and most common naturally occurring triplet. 25, 26 Ribozyme cleavage activity against selected sites in vitro
To determine the validity of the selection system and identify optimal anti-E6AP ribozymes, four of the selected sites were chosen and corresponding ribozymes were designed. Selected E6AP ribozymes identified by their proficiency of transcript hydrolysis at positions 354, 420, 687 and 1584 in the library context were reconstructed in their own individual expression vectors. In each case, the 12 bp sequence of stems I and III was deduced from the cleavage site on the assumption that hybridization took place by Watson-Crick base pairing. 0 ends of the cleavage products were identified by LA-PCR as follows. Reverse transcription was carried with gene-specific primers, and the 5 0 -phosphorylated, 3 0 -cordycepin-blocked linker oligonucleotide was ligated to first-strand cDNA with T4 RNA ligase. PCR amplification was performed with nested E6AP-specific primers and primers specific for known linker sequence. The sequence of the amplified cleavage product was determined by alignment with a dideoxy sequencing ladder generated from the corresponding nested primer.
Fig 3 Identification of cleavage products by sequence alignment.
Amplified cleavage products were separated by 6% denaturing PAGE and visualized by phosphorimaging. LA-PCR was performed following cleavage reactions in the presence (+) or absence (À) of the random ribozyme library in two independent experiments (1, 2). The identity of products (*) was identified by sequence alignment with a dideoxy sequencing ladder (G, A, T, C).
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These were then used to generate ribozyme RNA for evaluation of their specific activity against the full-length E6AP transcript in vitro. As expected, all of the ribozymes revealed efficient kinetic activity, with k react /K M in the range 10 3 -10 4 /M s ( Table 2 ). Ribozyme 420 demonstrated the highest reaction rate, but the overall efficiency was somewhat compromised by a higher K M , whereas Rz354 showed comparable cleavage efficiency due to its low K M despite having a two-fold lower k react . The in vitro kinetic data of the four selected ribozymes generally correlated with their activity in the selection system.
Efficacy of anti-E6AP ribozymes in HeLa cells
To evaluate the biological activity of the characterized ribozymes, the ribozymes were cloned into the 3 0 end of the neomycin resistance gene in the pIND vector and stably expressed as chimeric molecules in HeLa cells. The intracellular efficacy of the selected ribozymes in downregulating E6AP gene expression was initially examined at the protein level. As shown in Fig 4, the E6AP protein level was reduced in all the ribozyme-expressing cells relative to vector control. In particular, the ribozymes targeted to positions 687 and 1584 corresponding to HeLaRz4 and 5 were shown to be effective in reducing cellular E6AP (Fig 4) . In further experiments, the ribozyme-expressing cell line HeLaRz5 was found to display the most consistent suppression of E6AP and was therefore used for subsequent investigation of the cellular impact of this suppression under various conditions.
E6AP gene suppression and apoptosis
As E6AP is involved in the ubiquitination of proteins associated with key cellular functions, [3] [4] [5] [6] [7] to examine the biological implications of its suppression in HPV-positive cells, we observed their individual DNA content by FACS analysis. Under normal growth conditions, there was no observable change in the cell-cycle profile associated with ribozyme-mediated reduction in E6AP. However, when these cells (HeLaRz5) were exposed to the cytotoxic drug mitomycin C (MMC) there was a significant increase in the number of cells in the sub-G1 region of the histogram compared to the MMC-treated vector control cells (Fig 5) . Cells in the sub-G1 peak have lost genetic material and are typically apoptotic -hence the ribozyme-expressing cells appeared to be sensitized to cell death induced by the DNA-damaging agent MMC.
p53 accumulation in anti-E6AP ribozyme-expressing cells E6AP has been identified as the E3 ubiquitin-protein ligase involved in the HPV E6-stimulated degradation of p53. 2, 27 Recently, it has been shown that restoration of p53 levels can be accomplished by the suppression of E6AP with antisense reagents. 28 As expected, we also saw Where cleavage products were detected in the vicinity of two closely positioned potential target sites, both position (*) and sequences (z) were noted. E6AP gene suppression using ribozymes Y Kim et al an increase in the p53 level in response to the reduction of E6AP in the anti-E6AP ribozyme-expressing cells (Fig 6) .
After treatment with MMC, we observed induction of p53 in all cell lines which was consistent with earlier studies; 23 however, this occurred to the greatest extent in ribozymeexpressing cells such that the relative difference compared to the vector only cells was retained.
Bak accumulation in anti-E6AP-expressing cells
E6AP has recently been shown to display ubiquitin-ligase activity for the proapoptosis Bcl-2 family member Bak in HPV18-positive cells. 5 This reduction of Bak expression was thought to be a significant factor in the repression of cell death in these cells. Interestingly, we also observed a substantial increase in Bak expression in the E6AP ribozyme-expressing cells after MMC treatment compared to the vector control (Fig 6c) .
c-myc accumulation in anti-E6AP-expressing cells
The c-myc oncogene has also been identified as an E6AP substrate for HPV E6-mediated degradation. 3 Our analysis of c-myc protein in E6AP ribozyme-expressing cells demonstrates that like p53, its levels can also be increased with respect to the vector control as a consequence of E6AP gene suppression (Fig 6) . With the addition of MMC treatment, c-myc protein levels in contrast to the effect on p53 levels were substantially reduced in all cell lines. However, while c-myc expression was diminished by MMC treatment, the relative difference in the c-myc level between E6AP ribozyme-expressing and control cells was sustained (Fig 6) .
Gene expression profile
The ubiquitin-ligase activity E6AP enables it to exert considerable influence over a range of protein substrates, which in turn determine the fate of cells. When the substrates are transcription factors such as c-myc, E6AP can further extend its influence through its effect on transcriptional activity. In addition, E6AP itself has been shown to be capable of modulating transcriptional activity directly by interactions between its coactivation domain and members of the nuclear hormone receptor superfamily. 9 In order to explore the downstream transcriptional implications for E6AP gene suppression, we compared the E6AP ribozyme-expressing cells with the vector control cells by gene expression profiling using the Clonetech Atlas Array system. The Atlas array contains probes for genes from a broad range of functional groups including cell growth, cell death, signal transduction, DNA repair and immune function. Out of the 588 genes screened, nine were consistently found to be differentially expressed and from this group seven were confirmed by conventional Northern blot analysis and four displayed substantial differences (Fig 7) .
Discussion
Target site selection for ribozymes
Identifying regions of accessibility within long RNA transcripts poses a formidable challenge for hybridization-based gene inactivation strategies. Combinatorial screening methods present one of the most efficient means of examining every potential site in a minimal number of reactions. This approach has been used in defining accessible sites in vitro for antisense oligonucleotides, 29 ribozymes [13] [14] [15] and catalytic DNA. 20 Lieber and Strauss 18 first reported the use of hammerhead ribozymes in a nondirected approach to target site selection. By using a library of ribozymes with a conserved core and randomized hybridizing arms, vast numbers of NUH sites of the target RNA were screened simultaneously. As the screening method used conventional ribozymes, it concomitantly precluded the selection of sites that may have been incompatible with hammerhead assembly. In theory, this strategy presents the best way to select the most efficient ribozyme for any given target. However, the technical difficulty of identifying the positions of ribozyme accessibility posed a significant drawback.
In the present study, a similar approach was taken with substantial modifications. Firstly, it was possible to expedite the construction of the random ribozyme library by directly using PCR-generated templates rather than a plasmid library. In doing so, both the representation of the library and technical feasibility of ribozyme library production are markedly improved. Also, significant improvements were made in the method of cleavage product detection by using LA-PCR. This modification increased specificity through ligation of a single-stranded oligonucleotide rather than homopolymeric tailing. Most importantly, introduction of LA-PCR in the detection step will certainly increase the sensitivity of the method. 19, 30, 31 Finally, sequence alignment was used, thereby eliminating the need for cloning and sequencing of individual LA-PCR products. The sum of these modifications resulted in the ability to identify favorable ribozyme target sites more quickly and efficiently.
The most effective cleavers against the long folded E6AP transcript did not target GUC sites which are the most susceptible in short substrates, instead there was a tendency to target other NUH cleavage sites. This was quite significant as it demonstrated that in this system target site position and its effect on the kinetics of ribozyme-substrate binding are the rate limiting in long folded RNA. This means that the rate of the cleavage step does not necessarily feature in the ribozyme selection process. It also highlights the importance of an irrational target site selection process, as rational selection based on GUC triplets would not have been as effective against this target.
E6AP gene suppression
E6AP is capable of interacting with cellular control networks on a number of different levels both through its ubiquitin-ligase activity and its coactivation domain. While the full extent of its influence is not yet defined, its ability to regulate the steady-state levels of key mediators in the apoptosis pathway, such as p53, c-myc and Bak, alone is indicative of high biological significance. 2, 3, 5 When associated with HPV E6, E6AP plays a critical role in the immortalization and transformation of HPV-positive cells. It also appears to be central in attenuating the HPV-positive cells' response to cytotoxic drugs such as MMC. In this study, we have used anti-E6AP ribozyme expression to examine the effect of E6AP gene suppression in HPV18-positive cells under normal growth conditions and in response to strong apoptotic stimuli.
At the molecular level, we observed direct confirmation of ribozyme activity with a 60% suppression of the target protein E6AP in the ribozyme-expressing cells. In addition, we were able to directly observe some of the consequences of this suppression with increases in the E6AP substrates p53, Bak and c-myc. With the addition of the cytotoxic drug MMC, the levels of all three of these proteins changed substantially with a generalized induction of p53 and reduction of c-myc. However, despite these global changes, the respective difference between the anti-E6AP ribozyme-expressing cells and the vector control was the same as untreated cells with higher relative levels of each of these protein substrates.
The effect of E6AP suppression was also examined at the phenotypic level by the measurement of DNA content in individual cells by flow cytometry. Under normal growth conditions, no difference in the cell-cycle profile was visible between ribozyme-expressing and vector control cells. However, in the presence of the DNA damage-inducing drug MMC, there was a substantial increase in the sub-G1 population of cells in the group expressing the anti-E6AP ribozyme. This indicated that the ribozyme-expressing cells had been sensitized to MMC-induced apoptosis as a result of the reduction in E6AP. This effect was probably due to the increase in p53 and Bak, which were found to occur in response to suppression of E6AP, although there are other relevant substrates for this ubiquitin-ligase such as c-myc. These findings support the hypothesis that E6AP-related suppression of p53 and other proteins involved in the response to apoptotic stimuli increases the HPV-positive tumors' resistance to cytotoxic therapy. The ability to potentiate the sensitivity of these tumor cells to apoptosis means that E6AP could be a candidate drug target. Therapeutic inhibitors of E6AP should be capable of elevating the potency of traditional cytotoxic agents, particularly those that stimulate a response through the p53 pathway. The far-reaching influence of E6AP and its potential for even more unknown functions led us to explore the impact of its suppression on the cells' gene expression profile. From this analysis, we found that four genes were consistently differentially expressed, including HSP27 and clusterin, which were downregulated, and NM23-H2 and NSEP, witch were upregulated. Interestingly, the most pronounced changes that occurred in the ribozymeexpressing cells were the decrees in HSP27 and clusterin expression. Both of these genes have been shown to be involved in cellular resistance to apoptosis in response to stress. In the case of HSP27, constitutive expression has been shown to abrogate apoptosis induced by both Fas/ APO-1 ligand and the protein kinase C inhibitor staurosporin in L929 cells. 32 Similarly, an upregulation of clusterin expression has been shown to attenuate apoptosis and confer resistance to the cytotoxic drug doxorubicin. 33 These findings fit well with the phenotype displayed by the ribozyme-expressing cells and suggest that there may be a mechanism for transcriptional regulation of these genes that acts either directly or indirectly through the E6Ap substrates p53 or c-myc.
In the group of upregulated genes, NM23-H2 expression showed the most dramatic increase. Expression of this gene has been shown previously to be positively associated with cell proliferation and apoptosis possibly through its influence on c-myc gene expression. 34 These characteristics were also compatible with the observations in E6AP ribozyme-expressing cells with an increase in both c-myc and apoptosis.
Conclusion
An in vitro selection strategy was used to find the most efficient E6AP-cleaving hammerhead ribozyme. The ribozyme library used in this process contained combinatorial pool of binding arm sequences with the potential to cleave almost any RNA sequence with an NUH triplet. As the abundance of individual member of the library is rare, a highly sensitive methodology based on LA-PCR was established, which enables direct identification of cleavage sites from very small quantities of fragmented RNA. After characterizing the in vitro cleavage activity of ribozymes selected by this process, they were each cloned into an expression vector that was subsequently transfected into HPV18-positive HeLa cells. Some of these anti-E6AP ribozyme-expressing cell lines were found to have a reduced concentration of E6AP protein, whereas the p53 and c-myc levels were increased. Treatment of these cells with the cytotoxic drug MMC produced an even greater increase in both the p53 content and the number of cells entering into apoptosis compared to the vector control cells that did not express a ribozyme. This finding reconfirms that E6AP in conjunction with E6 protein attenuates the apoptotic pathway in HPV-positive cells via its effect on p53, c-myc, Bak and probably other proteins, through its ubiquitin-ligase activity. Gene expression profiling of E6AP-deficient cells suggests that other molecules in this pathway may be influenced through transcriptional regulation from factors regulated by E6AP, such as c-myc, or perhaps directly by E6AP's own coactivation activity. Regardless of the mechanism, E6AP is clearly a potential target for therapeutic intervention, particularly in HPV-positive tumor cells where it appears to be instrumental in suppressing apoptotic signaling in response to cytotoxic drugs.
